Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00865462 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fed Conditions
A Phase 1 study of Healthy, sponsored by Actavis.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00865462 is a Phase 1 study of Healthy that has completed, run by Actavis. The registered enrollment target is 30 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00865462, a Phase 1 study of Healthy, has completed, sponsored by Actavis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the rate and extent of absorption of Abrika Bupropion 150 mg XL Tablet to that of Wellbutrin XL® 150 mg Tablet after a single, one-tablet dose in subjects fed a standard meal.
Conditions Studied
Interventions
- DRUG Abrika Bupropion 150 mg XL Tablet, single dose
- DRUG Wellbutrin XL® 150 mg Tablet, single dose
Study Locations (1)
Florida
- SFBC Ft. Myers, Inc. - Fort Myers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-07 |
| Est. Completion | 2004-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00865462
The ClinicalTrials.gov registry entry for NCT00865462 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (95% lower). The listed sponsor is Actavis, which has 79 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Abrika Bupropion 150 mg XL Tablet, single dose is the first listed.
NCT00865462 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT00865462 about?
NCT00865462 is a clinical study titled "A Relative Bioavailability Study of Bupropion XL 150 mg Tablets Under Fed Conditions". The purpose of this study is to compare the rate and extent of absorption of Abrika Bupropion 150 mg XL Tablet to that of Wellbutrin XL® 150 mg Tablet after a single, one-tablet dose in subjects fed a standard meal.
What is the current status of trial NCT00865462?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2004-07. Estimated completion is 2004-07.
What conditions does trial NCT00865462 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT00865462?
The interventions under investigation include: Abrika Bupropion 150 mg XL Tablet, single dose (DRUG), Wellbutrin XL® 150 mg Tablet, single dose (DRUG).
Who is sponsoring clinical trial NCT00865462?
This trial is sponsored by Actavis, which has 79 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00865462 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.